Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine for treating diabetic nephropathy

A technology for drugs and raw materials, applied in the field of drugs for the treatment of diabetic nephropathy, can solve problems such as not achieving ideal therapeutic effects

Inactive Publication Date: 2015-07-29
THE THIRD PEOPLES HOSPITAL OF QINGDAO
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, the western medicine treatment of diabetic nephropathy is mainly through the control of blood sugar, blood pressure, and regulation of lipid metabolism, but the ideal therapeutic effect has never been achieved. When the disease develops to the stage of renal failure, dialysis treatment can only be used to maintain life.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine for treating diabetic nephropathy

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0053] The present invention also provides the preparation method of above-mentioned medicine, it comprises:

[0054] The first step is to take Angelica, Astragalus, Blue Buzheng, Black Sesame, Eclipta, Desmodium, Cornus officinalis, Radix Paeoniae Alba, and Shayuanzi, grind them separately, and mix them together to obtain a mixture. 10 times the amount of ethanol with an alcohol concentration of 70% to 80% is refluxed and extracted three times, and the extracts are combined, concentrated under reduced pressure at 60°C to obtain an extract with a relative density of 1.10 to 1.20, and ethanol is added to make the concentration of ethanol reach 60 ~90%, place, precipitate, separate the supernatant, concentrate, and get the concentrate. The obtained concentrate is put on a macroporous adsorption resin column, and eluted with ethanol gradient with a concentration of 30% to 90%, and the collection concentration is 60% to 80% % ethanol eluent, reclaim solvent, obtain dry paste, be g...

Embodiment 1

[0061] Example 1 Tablet 1

[0062] Take 38g of angelica, 57g of astragalus, 35g of blue cloth, 30g of black sesame, 44g of Eclipta, 28g of desmodium, 34g of dogwood, 35g of white peony and 33g of shayuanzi, grind them separately, mix them together to obtain a mixture, add 2.5kg of Reflux extraction with ethanol with an alcohol concentration of 80%, extract three times, combine the extracts, concentrate under reduced pressure at 60°C to obtain an extract with a relative density of 1.15, add ethanol to make the concentration of ethanol reach 70%, place, precipitate, and separate The clear liquid is concentrated to obtain the concentrate, and the obtained concentrate is put on a macroporous adsorption resin column, and is eluted with a gradient of ethanol with a concentration of 30% to 90%, and the ethanol eluate with a concentration of 60% to 80% is collected, and the solvent is recovered to obtain Dry paste, crushed into powder, 35g of motherwort, 30g of red peony root, 23g of ...

Embodiment 2

[0063] Example 2 Toxicity Verification

[0064] 1. Acute toxicity test report

[0065] Test method: take the tablet 1 of Example 1 of the present invention as an object, select 20 adult white mice for the test, and administer 150 times the clinical daily dosage to 20 white mice in the test group in the large intestine, and observe for 7 days. Results All the 20 white mice survived, and no abnormality was found in their activities, diet, hair and excrement, and no toxic reaction was found.

[0066] 2. Chronic toxicity test report:

[0067] Get 60 Wistar rats, body weight 100-200g, half male and half male, and randomly divide into 3 groups: set up 2 drug groups, the high-dose group (Group I) is 6g / kg / day, and the low-dose group (Group II) is 3g / kg / day and the matched group, the tablet 1 prepared in embodiment 1 was made into 40% and 20% suspension, administered by intragastric administration at 1.5ml / 100g, administered once a day, continuously administered for 60 days, The c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a medicine for treating diabetic nephropathy. The medicine comprises raw materials as follows: Chinese angelica, astragalus membranaceus, aleppo avens, motherwort herb, red paeony root, four-leaf clover, moellendorf's spidemoss herb, trifoliate acanthopanax root, bamboo orchid, cherokee rose fruit, black sesame, yerbadetajo herb, medicinal changium root, turmeric, longhairy antenoron herb, common macrocarpium fruit, white paeony root and flastem milkvetch seeds. The medicine can improve clinical symptoms of a patient suffering from diabetic nephropathy, reduce urine protein and delay deterioration of kidney functions, so that the life quality of the patient can be improved.

Description

technical field [0001] The invention relates to the technical field of traditional Chinese medicine, in particular to a medicine for treating diabetic nephropathy. Background technique [0002] Diabetic nephropathy (diabetic nephropathy DN) is glomerular sclerosis caused by diabetic microangiopathy, and its clinical manifestations mainly include increased glomerular filtration rate, proteinuria, edema, and nephrotic syndrome. As one of the most serious complications of diabetes mellitus DM, DN can also induce other vascular complications. At the same time, end-stage renal failure (ESRD) caused by diabetic nephropathy is becoming the main cause of life-threatening diabetes patients, which seriously affects the quality of life of patients and consumes a lot of medical resources. Genetic factors, protein nonenzymatic glycosylation, enhanced oxidative stress, protein kinase C (PKC) activation, hemodynamic abnormalities, proinflammatory cytokines, tumor necrosis factor-α (TNF-α)...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K36/9066A61P3/10A61P13/12
Inventor 刘泽涛于莉程绍云范爱秀
Owner THE THIRD PEOPLES HOSPITAL OF QINGDAO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com